胰岛素抵抗和代谢综合征与早期子宫内膜癌患者保留生育功能治疗后复发的关系

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1010 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the relationship between insulin resistance (IR) and metabolic syndrome (MetS) and the recurrence of early endometrial cancer patients treated with fertility preservation therapy. Methods The clinical data of 111 patients with early endometrial carcinoma who underwent fertility preservation therapy in No.910th Hospital of PLA Joint Service Support Force from January 2016 to December 2019 were retrospectively analyzed. The patients were divided into recurrent group (n=38) and non-recurrent group (n=73) according to whether they recurred within 3 years after treatment. COX risk ratio regression model was used to explore the factors that affected the recurrence of early endometrial cancer patients treated with fertility preservation therapy, and Kaplan-Meier method was used to analyze the relapse-free survival (RFS) characteristics of patients with different IR and MetS. Results BMI≥ 25 kg/m² (OR=2.723, 95% CI: 1.468-5.048,P=0.001),IR (OR=9.542, 95% CI: 1.468-5.048, P＜0.001),MetS (OR=4.917,95% CI:2.610-9.260, P＜0.001) and maintenance therapy (OR=0.381,95% CI: 0.241-0.600,P＜0.001) were independent risk factors for the recurrence in patients with early endometrial cancer after fertility preservation therapy. Kaplan-Meier method showed that RFS of patients with IR was significantly worse than that of the patients without IR (χ²=14.329, P＜0.001), and there was no significant difference in RFS between the patients with and without MetS (χ²=1.558,P=0.212). The RFS of IR+ and MetS+ group was significantly worse than that of IR and MetS group and IR+ or MetS+ group (χ²=24.436,P<0.001). Conclusions Both IR and MetS are risk factors for the recurrence of early endometrial cancer in patients treated with fertility preservaion therapy, and they may play a synergistic role in its prognosis and recurrence.

Key words： endometrial carcinoma preservance of fertility function recurrence insulin resistance metabolic syndrome

Received: 20 May 2023

ZTFLH:

R711.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Julian
	DONGJixiu
	LIANG Huixia
	LINShuyuan
	HU Yan

Cite this article:

LIU Julian,DONGJixiu,LIANG Huixia等. Relationship between insulin resistance and metabolic syndrome and recurrence of early endometrial cancer patients with fertility preservation therapy[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(1): 38-43.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I1/38

[1]	中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6):501-512.
[2]	中国研究型医院学会妇产科专业委员会.早期子宫内膜癌保留生育功能治疗专家共识(2022年版)[J].中国妇产科临床杂志, 2023, 24(2):215-219.
[3]	Kalampokas E, Giannis G, Kalampokas T, et al. Current approaches to the management of patients with endometrial cancer[J].Cancers (Basel), 2022, 14(18):4500.
[4]	中华医学会妇产科分会病理学组, 中华医学会病理学分会女性生殖系统疾病病理学组(协作组), 中国研究型医院学会超微与分子病理学分会妇儿学组.子宫内膜癌保育治疗前后病理评估专家共识[J].中华病理学杂志, 2022, 51(11):1110-1114.
[5]	Coakley K, Wolford J, Tewari K S. Fertility preserving treatment for gynecologic malignancies: a review of recent literature[J].Curr Opin Obstet Gynecol, 2020, 32(1):51-56.
[6]	王益勤,王建六.子宫内膜癌保留生育功能治疗现状及进展[J].中国计划生育和妇产科, 2022, 14(8):5-8
[7]	何翊姣, 王益勤, 戴一博, 等.子宫内膜非典型增生及早期子宫内膜癌初次保留生育功能治疗的临床疗效[J].中华肿瘤杂志, 2022, 44(3):291-296.
[8]	Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk [J].Curr Opin Urol, 2022, 32(6):594-597.
[9]	Kasius J C, Pijnenborg J M A, Lindemann K, et al. Risk stratification of endometrial cancer patients: FIGO Stage, biomarkers and molecular classification[J]. Cancers (Basel), 2021, 13(22):5848.
[10]	中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
[11]	Chen M, Jin Y, Li Y, Bi Y, et al. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer[J].Int J Gynaecol Obstet, 2016, 132(1):34-38.
[12]	Wang Y, Zhou R, Wang H, et al. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia[J].Int J Gynecol Cancer, 2019, 29(4): 699-704.
[13]	Yang X, Li X, Dong Y, et al. Effects of Metabolic Syndrome and Its Components on the Prognosis of Endometrial Cancer[J].Front Endocrinol (Lausanne), 2021, 12: 780769.
[14]	Mili N, Paschou S A, Goulis D G, et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations [J].Endocrine, 2021, 74(3):478-497.
[15]	聂明月, 王文莉, 叶红.子宫内膜非典型增生患者行保留生育功能治疗的预后分析[J].中国计划生育和妇产科, 2022, 14(8):60-64.
[16]	Kitson S, Ryan N, MacKintosh M L, et al. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer[J].Cochrane Database Syst Rev, 2018, 2(2):CD012513.
[17]	Wang Y, Zhou R, Wang H, et al. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia [J]. Int J Gynecol Cancer, 2019, 29(4): 699-704.
[18]	Park J Y, Kim D Y, Kim J H, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002) [J].Eur J Cancer, 2013, 49(4):868-874.
[19]	Lai Y, Sun C. Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer [J].Oncol Lett, 2018, 15(2): 2173-2178.
[20]	Tian W, Teng F, Zhao J, et al. Estrogen and insulin synergistically promote type 1 endometrial cancer progression[J].Cancer Biol Ther, 2017, 18(12):1000-1010.
[21]	张赫, 孔为民.代谢因素与子宫内膜不典型增生及子宫内膜癌的相关性列线图模型[J].肿瘤学杂志, 2021, 27(7):566-571.
[22]	Winarto H, Habiburrahman M, Febriana I S, et al. Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women [J].Oncol Lett, 2022, 25(1): 23.
[23]	Eleveld T F, Schild L, Koster J, et al. RAS-MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma [J].Cancer Res, 2018, 78(21):6297-6307.